Goal 2: Reduce Human Disease

Submitted by (@nhlbiforumadministrator)

Lung Transplantation

As in other solid organ transplants, adherence to the medical regimen after adult and pediatric lung transplantation is less than ideal and contributes to poor health outcomes. a) How can we improve the prediction of which lung transplant recipients are at greatest risk for nonadherence? b) What are the most efficient and effective ways of assessing nonadherence in the clinical setting? c) Conduct clinical trials of ...more »

Voting

1 net vote
1 up votes
0 down votes
Active

Goal 3: Advance Translational Research

Submitted by (@nhlbiforumadministrator)

Bone Marrow Stem Cell Transplant in Peds sibling matched SCD

There is a need to improve accessibility of Bone Marrow Stem Cell Transplantation (BMSCT) for Sickle Cell Disease patients who are most likely to benefit from this treatment option. 1. Building a culture of trust between and among primary care providers, specialists, patients/families, and other stakeholders 2. Consensus building around BMSCT as an acceptable treatment alternative (as opposed to another research endeavor) ...more »

Voting

52 net votes
80 up votes
28 down votes
Active

Goal 3: Advance Translational Research

Submitted by (@nhlbiforumadministrator)

Achieving Transplantation Tolerance in Recipients of Heart and Lung Allografts

Despite improvements in the early post-transplant survival of thoracic organs, registry data show that the graft half-life is only 11 years for heart recipients and 5 years for lung recipients. Infection accounts for 33% of cardiac and 40% of lung transplant recipient death between day 31 and one year post transplant. After 5 years, cardiac allograft vasculopathy (30%), and malignancy (23%) cause most cardiac recipient ...more »

Voting

7 net votes
24 up votes
17 down votes
Active

Goal 3: Advance Translational Research

Submitted by (@shahram.mori.md)

Should Allogeneic stem cell transplantation be considered as an upfront treatment in high risk double hit DLBCL?

Double-hit lymphomas (DHL’s) are high-grade B-cell lymphomas characterized by chromosomal rearrangements of MYC gene with BCL2 and less commonly, BCL6.Large analysis of patients with de novo DLBCL have shown that conventional chemotherapy does not improve the survival of DHL Aggressive upfront chemotherapy followed by autologous stem cell transplantation (ASCT) has become a standard treatment in eligible patients. Retrospective ...more »

Voting

2 net votes
3 up votes
1 down votes
Active

Goal 2: Reduce Human Disease

Submitted by (@js2745)

The role of Extracorporeal Photopheresis (ECP) in the prophylaxis and treatment of acute & chronic Graft Versus Host Disease

In Acute Graft Versus Host Disease (aGVHD), we would like to examine whether early and intensified delivery of ECP as part of standard prophylaxis will decrease overall corticosteroid exposure while preserving expected relapse rates in patients undergoing unrelated donor hematopoietic stem cell transplantation (HSCT). Chronic GVHD (cGVHD) is common after HSCT (30-50% recipients) and is a major contributor to late transplant-related ...more »

Voting

103 net votes
126 up votes
23 down votes
Active

Goal 3: Advance Translational Research

Submitted by (@mehdihamadani)

Modulating Immune Checkpoints to Enhance Curative Potential of Autologous Transplantation in classical Hodgkin lymphoma (cHL)

PD-L1 and PD-L2, engage PD-1 receptors on activated T cells and induce T-cell exhaustion. Antibody-mediated PD-1 blockade has already been successfully exploited as a therapeutic strategy in solid tumors. PD-L1 is expressed on suppressor immune cells in the tumor microenvironment and in cHL tumors. PD1 blockade has shown clinical activity in cHL. Disease relapse, post autoHCT; however remains the most common cause of ...more »

Voting

26 net votes
46 up votes
20 down votes
Active

Goal 1: Promote Human Health

Submitted by (@nhlbiforumadministrator)

Host and environmental factors effect on transplantation biology and regenerative medicine

How does inflammation and cell injury induce the immune system during transplant rejection? How do we control immune responses to enable cell- and tissue-regenerative strategies? • How does inflammation and cell injury induce the immune system during transplant rejection? • How do we control immune responses to enable cell and tissue regenerative strategies? • How do we use iPS cell based and gene editing based therapies ...more »

Voting

34 net votes
48 up votes
14 down votes
Active